Treeway B.V.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk Brings Embark Home After F

After many attempts and failures to bring a disease-modifying therapy forward for Alzheimer’s disease, the triumph of Eisai Co., Ltd. / Biogen, Inc. ’s amyloid protofibril-clearing antibody lecanemab